Gland Pharma gains on partnering with Neuland Laboratories
Gland Pharma is currently trading at Rs. 2570.70, up by 25.00 points or 0.98% from its previous closing of Rs. 2545.70 on the BSE.
The scrip opened at Rs. 2545.90 and has touched a high and low of Rs. 2601.00 and Rs. 2545.90 respectively. So far 124124 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2634.00 on 04-Aug-2026 and a 52 week low of Rs. 1575.00 on 16-Mar-2026.
Last one week high and low of the scrip stood at Rs. 2634.00 and Rs. 2491.35 respectively. The current market cap of the company is Rs. 42540.78 crore.
The promoters holding in the company stood at 51.77%, while Institutions and Non-Institutions held 39.18% and 9.05% respectively.
Gland Pharma and Neuland Laboratories have entered into a long-term strategic CDMO partnership. Under the partnership, the company will establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products.
The collaboration combines Neuland's Complex API development and manufacturing capabilities including deep expertise in complex chemistry, process development, custom manufacturing having a strong track record of serving global innovator and generic pharmaceutical companies; with the company's global sterile manufacturing expertise and strong regulatory compliance track record, to serve growing worldwide demand for sterile APIs used in microparticle depot products and other complex sterile APIs.
The collaboration represents a significant expansion of the relationship between the two companies, creating a dedicated manufacturing platform that aligns their complementary capabilities under a long-term strategic partnership. Under the collaboration, the company will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs.
The facility will be constructed and operated to cGMP, USFDA and EU standards, and will be backed by the company's proven aseptic manufacturing expertise. Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. The suite will be designed to add around 1400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth. The partnership is expected to enhance supply resilience globally by combining Neuland's development and regulatory expertise with the company's manufacturing capabilities.
